Vanguard Intl Hi Div Yld Idx ETF

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Is Global Leader in Consumer Healthcare Business

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 2.0 billion pounds from the sale of its consumer healthcare products, which is year-over-year (or YoY) growth of 5% on a reported basis and 2% on a constant exchange rate (or CER).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Nucala May Be a Game-Changing Product in Respiratory Segment

    On December 12, 2017, the FDA expanded Nucala’s label and approved the therapy for patients suffering from eosinophilic granulomatosis with polyangiitis (or EGPA).

    By Margaret Patrick
  • uploads///EARNINGS ESTIMATES
    Earnings Report

    Will ZBH Beat Wall Street Earnings Estimates in 4Q17?

    Zimmer Biomet Holdings (ZBH) accounts for ~0.17% of the total holdings of the Vanguard International High Dividend Yield ETF (VYMI). Zimmer Biomet Holdings plans to announce its 4Q17 and fiscal 2017 earnings results on January 30.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s CVMD Products Performed in 3Q17

    The CVMD segment reported revenues of $1.8 billion during 3Q17, a 4% decline in operating revenues driven by lower sales of Bydureon, Crestor, Onglyza, and Seloken.

    By Mike Benson
  • uploads///Brilinta
    Company & Industry Overviews

    AstraZeneca’s Brilinta and Farxiga Posted High Growth in 3Q17

    Brilinta generated 9M17 revenues of ~$175.0 million from emerging markets, which reflected 29.0% YoY growth.

    By Daniel Collins
  • uploads///Tasigna
    Company & Industry Overviews

    How Novartis’s Tasigna Is Looking Now

    In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which with ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Immunology dermatology
    Company & Industry Overviews

    Investor Updates on Novartis’s Immunology and Dermatology Portfolio

    In 1H17, Novartis’s (NVS) Neoral/Sandimmune reported revenues of around $238 million, which reflected an ~8% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///HST DIV
    Real Estate

    Host Hotels & Resorts’ Dividend Yield over the Years

    Revenue and earnings Host Hotels & Resorts (HST), a hotel REIT, is involved in the possession and operation of US hotel properties. The company’s revenue was almost flat in 2015 and 2016, driven by rooms and food and beverages. Its operating costs and expenses rose 1%–2% in 2015 and 2016., while its interest expenses fell 32% […]

    By Amanda Lawrence
  • uploads///Chart  Resp
    Company & Industry Overviews

    Performance of AstraZeneca’s Respiratory Segment in 2Q17

    Pulmicort, a drug for the prevention of asthma attacks, reported revenues of $226 million during 2Q17, a 3% decline at constant exchange rates compared to 2Q16.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.